Study · Randomized controlled trial · n = 30 · 2017

13 results

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB

Diabetes, obesity & metabolism5 May 2017Cited by 539 (Europe PMC)

PMID28266779PMCIDPMC5573908DOI10.1111/dom.12932PepBankPUB-28266779

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide lowered ad libitum energy intake at lunch versus placebo (-1255 kJ).
In plain wordsIn adults with obesity, semaglutide led to eating less at lunch than placebo.
Peptide
Semaglutide
Outcome
DecreaseAd libitum energy intake at lunch
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Energy intake difference
−1255 kJ
lunch
Source sentences
Summary
lower ad libitum energy intake during lunch (-1255 kJ; P < .0001)
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677901
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide lowered ad libitum energy intake at the evening meal versus placebo.
In plain wordsIn adults with obesity, semaglutide led to eating less at the evening meal than placebo.
Peptide
Semaglutide
Outcome
DecreaseAd libitum energy intake at the evening meal
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
during the subsequent evening meal ( P = .0401)
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677902
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide lowered ad libitum energy intake from snacks versus placebo.
In plain wordsIn adults with obesity, semaglutide led to eating fewer snacks than placebo.
Peptide
Semaglutide
Outcome
DecreaseAd libitum energy intake from snacks
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
and snacks ( P = .0034), resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036 kJ; P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677903
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide reduced total energy intake across all ad libitum meals by 24% versus placebo (-3036 kJ).
In plain wordsIn adults with obesity, semaglutide cut total food intake over the day by 24% compared with placebo.
Peptide
Semaglutide
Outcome
DecreaseTotal ad libitum energy intake across the day
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Total energy intake difference
−3036 kJ
all ad libitum meals
Source sentences
Summary
resulting in a 24% reduction in total energy intake across all ad libitum meals throughout the day (-3036 kJ; P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677904
05HumanRandomized controlled trialEfficacy outcome
In adults with obesity, fasting overall appetite suppression scores improved with semaglutide versus placebo.
In plain wordsIn adults with obesity, appetite was suppressed more with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
IncreaseFasting overall appetite suppression score
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Fasting overall appetite suppression scores were improved with semaglutide vs placebo
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677905
06HumanRandomized controlled trialSafety outcome
In adults with obesity, nausea ratings were similar with semaglutide and placebo.
In plain wordsIn adults with obesity, nausea ratings were similar with semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeNausea ratings
Study
n = 30
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
nausea ratings were similar.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677906
07HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide was associated with less hunger than placebo.
In plain wordsIn adults with obesity, semaglutide was linked to less hunger than placebo.
Peptide
Semaglutide
Outcome
DecreaseHunger
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677907
08HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide was associated with fewer food cravings than placebo.
In plain wordsIn adults with obesity, semaglutide was linked to fewer food cravings than placebo.
Peptide
Semaglutide
Outcome
DecreaseFood cravings
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677908
09HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide was associated with better control of eating than placebo.
In plain wordsIn adults with obesity, semaglutide was linked to better control over eating than placebo.
Peptide
Semaglutide
Outcome
IncreaseControl of eating
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677909
10HumanRandomized controlled trialEfficacy outcome
In adults with obesity, semaglutide was associated with a lower preference for high-fat foods than placebo.
In plain wordsIn adults with obesity, semaglutide was linked to less liking for high-fat foods than placebo.
Peptide
Semaglutide
Outcome
DecreasePreference for high-fat foods
Study
n = 30
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide was associated with less hunger and food cravings, better control of eating and a lower preference for high-fat foods.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677910
11HumanRandomized controlled trialEfficacy outcome
In adults with obesity, resting metabolic rate adjusted for lean body mass did not differ between semaglutide and placebo.
In plain wordsIn adults with obesity, resting metabolic rate did not differ between semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeResting metabolic rate adjusted for lean body mass
Study
n = 30
Comparator
Placebo
Outcome group
Energy expenditure and thermogenesis · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
Resting metabolic rate, adjusted for lean body mass, did not differ between treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677911
12HumanRandomized controlled trialEfficacy outcome
In adults with obesity, 12 weeks of semaglutide reduced mean body weight from baseline by 5.0 kg.
In plain wordsIn adults with obesity, 12 weeks of semaglutide reduced body weight by 5.0 kg on average.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline
Study
n = 30
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Body weight change
−5 kg
from baseline
Source sentences
Summary
Semaglutide led to a reduction from baseline in mean body weight of 5.0 kg
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677912
13HumanRandomized controlled trialEfficacy outcome
In adults with obesity, the weight lost on semaglutide came predominantly from body fat mass.
In plain wordsIn adults with obesity, most of the weight lost on semaglutide was body fat.
Peptide
Semaglutide
Outcome
DecreaseBody fat mass
Study
n = 30
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg once weekly (dose-escalated) · subcutaneous · 12 weeksAs given in this study (human).
Source sentences
Summary
predominantly from body fat mass.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks of treatment with once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, in 30 subjects with obesity.
Report a problemFND-2826677913

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingNot applicableNCT07065383

Rebalancing the Fat Content of the Heart and Muscles

University of Aberdeenn = 601 Aug 2025 to est. 31 Jul 2028

Diabetes Mellitus Type 2

Trial page ClinicalTrials.govUpdated 30 Apr 2026

RecruitingPhase 4NCT06132477

Impact GLP-1 Agonists Following Bariatric

University of Missouri-Columbian = 1501 Feb 2024 to est. Jul 2030

Morbid Obesity · Metabolic Syndrome · Diabetes Mellitus · Hypertension · Obstructive Sleep Apnea of Adult

Trial page ClinicalTrials.govUpdated 21 Oct 2026

Status unknownPhase 4NCT05616052

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Huashan Hospitaln = 80est. 1 Dec 2022 to est. 1 Dec 2023

Weight Change, Body

Trial page ClinicalTrials.govUpdated 15 Nov 2022

CompletedPhase 1NCT02079870

Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Novo Nordisk A/Sn = 306 Mar 2014 to 7 Jan 2015

Diabetes · Metabolism and Nutrition Disorder · Obesity

Trial page ClinicalTrials.govUpdated 2 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.